At present, anti-angiogenic drugs combined with immunotherapy have made great progress in advanced HCC, and atezolizumab plus bevacizumab, apatinib plus CAM and SIN plus IBI305 (anti-vascular endothelial growth factor (VEGF) drug) have shown good prospects in first-line treatment [21–23]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.